loader
Please Wait
Applying Filters...

Zevra Therapeutics's list of EU CTD Dossiers, Marketing Authorizations, In, Out Licensing Opportunities & Finished Dosage Formulations aggregated by PharmaCompass

Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 3ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass
Left Arrow
Right Arrow

01

Brand Name : APADAZ

Luxepack
Not Confirmed
arrow

Brand Name : APADAZ

arrow
Luxepack
Not Confirmed

Zevra Therapeutics

Dosage Form : TABLET;ORAL

Brand Name : APADAZ

Dosage Strength : 325MG;EQ 6.12MG BASE

Packaging :

Approval Date : 2018-02-23

Application Number : 208653

Regulatory Info : DISCN

Registration Country : USA

blank

02

Brand Name : APADAZ

Discovery on Target
Not Confirmed
arrow

Brand Name : APADAZ

arrow
Discovery on Target
Not Confirmed

Zevra Therapeutics

Dosage Form : TABLET;ORAL

Brand Name : APADAZ

Dosage Strength : 325MG;EQ 4.08MG BASE

Packaging :

Approval Date : 2019-01-04

Application Number : 208653

Regulatory Info : DISCN

Registration Country : USA

blank

03

Brand Name : APADAZ

Discovery on Target
Not Confirmed
arrow

Brand Name : APADAZ

arrow
Discovery on Target
Not Confirmed

Zevra Therapeutics

Dosage Form : TABLET;ORAL

Brand Name : APADAZ

Dosage Strength : 325MG;EQ 8.16MG BASE

Packaging :

Approval Date : 2019-01-04

Application Number : 208653

Regulatory Info : DISCN

Registration Country : USA

blank